Jefferies Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Maury Raycroft has initiated coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and set a price target of $22.
December 26, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies has initiated coverage on Dianthus Therapeutics with a Buy rating and a price target of $22, which could positively influence the stock's performance.
Analyst ratings, especially from reputable firms like Jefferies, can significantly impact a stock's short-term performance. A Buy rating coupled with a price target that suggests substantial upside can lead to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100